Achiko AG Announces Corporate Update Webcast
16. November 2022 10:38 ET
|
Achiko AG
ZURICH, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”), a healthcare technology company that is developing new...
Achiko AG Production and Company Update
02. November 2022 07:34 ET
|
Achiko AG
Completing Production Pilot for Generation 2 of AptameX™ as a Precursor to Mass Commercial ProductionExpect to Commence Delivery to Sales and Marketing Contract with Nahdlatul Ulama on Commencement of...
Achiko AG Appoints New Chief Financial Officer
07. Oktober 2022 07:30 ET
|
Achiko AG
ZURICH, Switzerland, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”), a healthcare...
Achiko AG Publication of Annual Report and Annual Financial Statements 2021 to Occur by June 6, 2022
31. Mai 2022 07:30 ET
|
Achiko AG
ZURICH, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) announces that...
Achiko AG – Publication of Annual Report and Annual Financial Statements 2021 to Occur by May 31, 2022
29. April 2022 07:30 ET
|
Achiko AG
ZURICH, Switzerland, April 29, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that...
Achiko Secures up to USD$12.6 Million Equity and Debt Financing Lines with RiverFort Over Three Years
20. April 2022 07:30 ET
|
Achiko AG
ZURICH, Switzerland, April 20, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) announces the...
Achiko AG’s Shares Begin Trading on the OTCQB Market
20. Dezember 2021 07:30 ET
|
Achiko AG
ZURICH, Switzerland, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468; www.achiko.com) (“Achiko”, the “Company”), a global healthtech company which has...
Achiko’s Commercialization Update: Optimized Second-Generation Covid-19 Diagnostic Test Receives Full Product Registration Approval in Indonesia
08. Dezember 2021 07:50 ET
|
Achiko AG
Second-generation of AptameX, Achiko’s innovative DNA aptamer diagnostic test for Covid-19 has received full approval in Indonesia for five yearsProduction of the second-generation AptameX kits to...
Achiko’s Covid-19 DNA Aptamer-Based Rapid Testing Platform Update
24. November 2021 07:30 ET
|
Achiko AG
Pilot program in Indonesia is on track with positive results and support for Achiko’s proprietary, low-cost rapid Covid-19 diagnostic test, AptameX, alongside its sister digital passporting service...
Achiko Secures Initial Sales of AptameX Covid-19 Diagnostic Test
27. Oktober 2021 07:30 ET
|
Achiko AG
Achiko has received its first purchase order in Jakarta and Bali in Indonesia.The orders translate to 20,000 tests - while modest in size, the order is expected to pave the way to rapid adoption by...